Torilis japonica extract-generated intracellular ROS induces apoptosis by reducing the mitochondrial membrane potential via regulation of the AMPK-p38 MAPK signaling pathway in HCT116 colon cancer

International Journal of Oncology

Volumn 49, Issue 3, 2016, Pages 1088-1098

  Kim, Guen Tae ^a   Lee, Se Hee ^b   Kim, Young Min ^a  

^a Hannam University   (South Korea)

^b GeneChem Inc   (South Korea)

Author keywords

Apoptosis; Mitochondria membrane potential; Reactive oxygen species; Torilis japonica

Indexed keywords

ADENYLATE KINASE; CASPASE 3; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE P38; PLANT EXTRACT; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TORILIS JAPONICA EXTRACT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DOWN REGULATION; ENZYME REGULATION; FRUIT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; MEDICINAL PLANT; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TORILIS JAPONICA; TUMOR VOLUME; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETICS; HCT 116 CELL LINE; METABOLISM; MUTATION; VASCULAR PLANT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; COLONIC NEOPLASMS; HCT116 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MUTATION; PLANT EXTRACTS; REACTIVE OXYGEN SPECIES; TRACHEOBIONTA; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978472423     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3578     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.
3. Center MM, Jemal A and Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 18: 1688-1694, 2009.
4. Parkin DM, Whelan SL, Ferlay J and Storm H (eds): Cancer Incidence in Five Continents. Vol I to VIII. Cancer Base 7. IARC Press, Lyon, 2005.
5. Ito Y, Ioka A, Tanaka M, Nakayama T and Tsukuma H: Trends in cancer incidence and mortality in Osaka, Japan: Evaluation of cancer control activities. Cancer Sci 100: 2390-2395, 2009.
6. Giovannucci E: Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 31: 925-943, 2002.
7. Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A, Gansler T, Andrews KS and Thun MJ; American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee: American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 56: 254-281, quiz 313-314, 2006.
8. Colditz GA, Sellers TA and Trapido E: Epidemiology-identifying the causes and preventability of cancer? Nat Rev Cancer 6: 75-83, 2006.
9. Pan SY, Zhou SF, Gao SH, Yu ZL, Zhang SF, Tang MK, Sun JN, Ma DL, Han YF, Fong WF, et al: New perspectives on how to discover drugs from Herbal medicines: CAM's outstanding contribution to modern therapeutics. Evid Based Complement Alternat Med 2013: 627375, 2013.
10. Prindull G: Apoptosis in the embryo and tumorigenesis. Eur J Cancer 31A: 116-123, 1995.
11. Meier P, Finch A and Evan G: Apoptosis in development. Nature 407: 796-801, 2000.
12. Lee YK, Park SY, Kim YM, Kim DC, Lee WS, Surh YJ and Park OJ: Suppression of mTOR via Akt-dependent and-independent mechanisms in selenium-treated colon cancer cells: Involvement of AMPKalpha1. Carcinogenesis 31: 1092-1099, 2010.
13. Chien SY, Wu YC, Chung JG, Yang JS, Lu HF, Tsou MF, Wood WG, Kuo SJ and Chen DR: Quercetin-induced apoptosis acts through mitochondrial-and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells. Hum Exp Toxicol 28: 493-503, 2009.
14. Adams JM and Cory S: Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26: 61-66, 2001.
15. Harris MH and Thompson CB: The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 7: 1182-1191, 2000.
16. Martinou JC and Green DR: Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2: 63-67, 2001.
17. Jia L, Macey MG, Yin Y, Newland AC and Kelsey SM: Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. Blood 93: 2353-2359, 1999.
18. Griffin DE and Hardwick JM: Regulators of apoptosis on the road to persistent alphavirus infection. Annu Rev Microbiol 51: 565-592, 1997.
19. Hsu YT, Wolter KG and Youle RJ: Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 94: 3668-3672, 1997.
20. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
21. Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998.
22. Mikhailov V, Mikhailova M, Pulkrabek DJ, Dong Z, Venkatachalam MA and Saikumar P: Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane. J Biol Chem 276: 18361-18374, 2001.
23. Antonsson B, Montessuit S, Lauper S, Eskes R and Martinou JC: Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J 345: 271-278, 2000.
24. Antonsson B, Montessuit S, Sanchez B and Martinou JC: Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 276: 11615-11623, 2001.
25. Sundararajan R and White E: E1B 19K blocks Bax oligomerization and tumor necrosis factor alpha-mediated apoptosis. J Virol 75: 7506-7516, 2001.
26. Degterev A, Boyce M and Yuan J: A decade of caspases. Oncogene 22: 8543-8567, 2003.
27. Kim GT, Lee SH and Kim YM: Torilis japonica extract, a new potential EMT suppressor agent by regulation of EGFR signaling pathways. Int J Oncol 45: 1673-1679, 2014.
28. Kim GT, Lee SH, Kim JI and Kim YM: Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway and induces apoptosis by increasing the generation of intracellular ROS in a p53-independent manner. Int J Mol Med 33: 863-869, 2014.
29. Lee YK, Park SY, Kim YM, Lee WS and Park OJ: AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin. Exp Mol Med 41: 201-207, 2009.
30. Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, Bertoncelli L, Cooper EL and Cossarizza A: Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med 2011: 591356, 2011.
31. Weidner C, Rousseau M, Micikas RJ, Fischer C, Plauth A, Wowro SJ, Siems K, Hetterling G, Kliem M, Schroeder FC, et al: Amorfrutin C induced apoptosis and inhibits proliferation in colon cancer cells through targeting mitochondria. J Nat Prod 79: 2-12, 2016.
32. Zhang X, Chen M, Zou P, Kanchana K, Weng Q, Chen W, Zhong P, Ji J, Zhou H, He L, et al: Curcumin analog WZ35 induced cell death via ROS-dependent ER stress and G2/M cell cycle arrest in human prostate cancer cells. BMC Cancer 15: 866, 2015.
33. He G, He G, Zhou R, Pi Z, Zhu T, Jiang L and Xie Y: Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo. Biochem Biophys Res Commun 469: 1075-1082, 2016.
34. Tanigawa S, Fujii M and Hou DX: Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. Biosci Biotechnol Biochem 72: 797-804, 2008.
35. Lee YK, Hwang JT, Kwon DY, Surh YJ and Park OJ: Induction of apoptosis by quercetin is mediated through AMPKalpha1/ASK1/p38 pathway. Cancer Lett 292: 228-236, 2010.
36. Bouchet BP Caron de Fromentel C, Puisieux A and Galmarini CM: p53 as a target for anticancer drug development. Crit Rev Oncol Hematol 58: 190-207. 2006
37. Moll UM, Marchenko N and Zhang XK: p53 and Nur77/TR3-transcription factors that directly target mitochondria for cell death induction. Oncogene 25: 4725-4743, 2006.
38. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, et al: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913, 2005.
39. Oren M: Decision making by p53: Life, death and cancer. Cell Death Differ 10: 431-442, 2003.
40. Olivier M, Hollstein M and Hainaut P: TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2: a001008, 2010.
41. Cuadrado A, Lafarga V, Cheung PC, Dolado I, Llanos S, Cohen P and Nebreda AR: A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. EMBO J 26: 2115-2126, 2007.
42. Sanchez-Prieto R, Rojas JM, Taya Y and Gutkind JS: A role for the p38 mitogen-acitvated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 60: 2464-2472, 2000.